Developing treatment for sickle cell disease

Bibliography

• VERMYLEN C: Bone marrow transplantation in sickle cell anemia. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (1st edn). Cambridge Univ. Press, Cambridge, UK (2001):1073–1083.
   Google Scholar
• COHEN AR, PORTER JB: Transfusion and iron chelation therapy in thalassemia and sickle cell anemia. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. (1st edn). Cambridge University Press, Cambridge, UK (2001):979–1027.
   Google Scholar
• SORRENTINO BP, NIENHUIS AW: Prospects for gene therapy of sickle cell disease and thalassemia. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (1st edn). Cambridge Univ. Press, Cambridge, UK (2001):1084–1118.
   Google Scholar
• PAWLIUK R, WESTERMAN KA, FABRYME et al: Correction of sickle cell disease in transgenic mouse models by gene therapy. Science (2001) 294:2368–2371.
   PubMed Web of Science ®Google Scholar
• EDINGTON GM, LEHMANN H: Expression of the sickle-cell gene in Africa. Br. Med.J. (1955) 1:1308–1311.
   PubMed Web of Science ®Google Scholar
• WATSON J, STAHMAN AW, BILELLO FP: Significance of paucity of sickle cells in newborn negro infants. Am. Med. Sd. (1948) 215:419–423.
   PubMed Web of Science ®Google Scholar
• NAGEL RL, BOOKCHIN RM, LABIE D, WAJCMAN H, ISAAC-SADEYE WA„ HONIG GR: Structural basis for the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl. Acad. Sci. USA (1979) 76:670–672.
   PubMed Web of Science ®Google Scholar
• FELSENFELD G, MCGHEE J: Methylation and gene control. Nature (1982) 296:602–603.
   PubMed Web of Science ®Google Scholar
• VAN DER PLOEG LH, FLAVELL RA: DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. Cell (1980) 19:947–958.
   PubMed Web of Science ®Google Scholar
• DESIMONE J, HELLER P, HALL L, ZWIERS D: 5-Azacytidine stimulates fetal hemoglobin synthesis in anemia baboons. Proc. Nati Acad. Sci. USA (1982) 79:4428–4431.
   PubMed Web of Science ®Google Scholar
• CHARACHE S, DOVER G, SMITH K, TALBOT CC, JR., MOYER M, BOYER SH: Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the 7-8-13 globin gene complex. Proc. Natl. Acad. Sci. USA (1983) 80:4842–4846.
   Google Scholar
• LEY TJ, DESIMONE J, NOGUCHI CT et al.: 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood (1983) 62:370–380.
   PubMed Web of Science ®Google Scholar
• BOYER SH, BELDING TK, MARGOLET L, NOYES AN: Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science (1975) 188:361–363.
   PubMed Web of Science ®Google Scholar
• NAGEL RL, STEINBERG MH: Hemoglobins of the embryo and fetus and minor hemoglobins of adults. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (1st edn). Cambridge Univ. Press, Cambridge, UK (2001):197–230.
   Google Scholar
• DOVER GJ, BOYER SH, CHARACHE S, HEINTZELMAN K: Individual variation in the production and survival of F cells in sickle-cell disease. N Engl. Med. (1978) 299:1428–1435.
   PubMed Web of Science ®Google Scholar
• RUCKNAGEL DL, HANASH SH, SING CE WINTER WP, WHITTEN CE PRASAD AS: Age and sex effects on hemoglobin F in sickle cell anemia. In: Cellular and Molecular Regulation of Hemoglobin Switching. Grune & Stratton, New York, USA (1979):107–118.
   Google Scholar
• PAPAYANNOPOULOU TH, BRICE M, STAMATOYANNOPOULOS G: Stimulation of fetal hemoglobin synthesis in bone marrow cultures from adult individuals. Proc. Natl. Acad Sci. USA (1976) 73:2033–2037.
   PubMed Web of Science ®Google Scholar
• PAPAYANNOPOULOU T, BRICE M, STAMATOYANNOPOULOS G: Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc. Nati Acad. Sci. USA (1977) 74:2923–2927.
   PubMed Web of Science ®Google Scholar
• BLAU CA, CONSTANTOULAKIS P, AL-KHATTI A et al.: Fetal hemoglobin in acute and chronic states of erythroid expansion. Blood(1993) 81:227–233.
   PubMed Web of Science ®Google Scholar
• KRUH J: Effects of sodium butyrate a newpharmacological agent on cells in culture. Ma Cell Biochem. (1982) 42:65–82.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY PG, NEWSOME DA, FIBACH E, YOSHIDA M, SU MS: Induction of gamma-globin by histone deacetylase inhibitors. Blood (1997) 90:2075–2083.
   PubMed Web of Science ®Google Scholar
• GLAUBER JG, WANDERSEE NJ, LITTLEJA, GINDER GD: 5'-Flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells. Ma Cell Biol. (1991) 11:4690–4697.
   Web of Science ®Google Scholar
• PACE BS, LI QL, STAMATOYANNOPOULOS G: In vivo search for butyrate responsive sequences using transgenic mice carrying Ay gene promoter mutants. Blood (1996) 88:1079–1083.
   PubMed Web of Science ®Google Scholar
• IKUTA T, KAN YW, SWERDLOW PS, FALLER DV, PERRINE SP: Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood (1998) 92:2924–2933.
   PubMed Web of Science ®Google Scholar
• IKUTA T, AUSENDAS, CAPPELLINI MD: Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. USA (2000) 98:1847–1852.
   Web of Science ®Google Scholar
• BOOSALIS MS, BANDYOPADHYAY R, BRESNICK EH et al: Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood (2001) 97:3259–3267.
   PubMed Web of Science ®Google Scholar
• CONSTANTOULAKIS P, KNITTER G, STAMATOYANNOPOULOS G: On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood (1989) 74: 1963-1971.
   Google Scholar
• PERRINE SP, MILLER BA, FALLER DV etal.: Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. Blood(1989) 74:454–459.
   Google Scholar
• PERRINE SP, MILLER BA, GREENE MF et al.: Butyric acid analogues augment globin gene expression in neonatal erythroid progenitors. Biochem. Biophys. Res. Commun. (1987) 148:694–700.
   PubMed Web of Science ®Google Scholar
• PERRINE SP, GINDER GD, FALLER DV et al.: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the I3-globin disorders. N Engl. Med. (1993) 328:81–86.
   PubMed Web of Science ®Google Scholar
• SHER GD, GINDER GD, LITTLE J, YANG S, DOVER GJ, OLIVIERI NF: Extended therapy with intravenous arginine butyrate in patients with 13-hemoglobinopathies. N Engl. Med. (1995) 332:1606–1610.
   PubMed Web of Science ®Google Scholar
• DOVER GJ, BRUSILOW S, CHARACHE S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood (1994) 84:339–343.
   PubMed Web of Science ®Google Scholar
• BLAU CA, CONSTANTOULAKIS P, SHAW CM, STAMATOYANNOPOULOS G: Fetal hemoglobin induction with butyric acid: Efficacy and toxicity. Blood (1993) 81:529–537.
   PubMed Web of Science ®Google Scholar
• ATWEH GE SUTTON M, NASSIF I et al.:Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood(1999) 93:1790–1797.
   Google Scholar
• •These observations provide hope for a new and effective method of butyrate treatment of sickle cell.
   Google Scholar
• STEINBERG MH, RODGERS GP: Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore) (2001) 80:328–344.
   PubMed Web of Science ®Google Scholar
• RESAR L, FITZPATRICK LK, FRIEDMANN AM, BRUSILOW S, DOVER GJ: Induction of fetal hemoglobin synthesis in children with sickle cell anemia on oral sodium phenylbutyrate. Blood (1999) 94:417a.
   PubMed Web of Science ®Google Scholar
• COLLINS AF, DOVER GJ, LUBAN NLC: Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy. Blood(1994) 84:1690–1691.
   PubMed Web of Science ®Google Scholar
• SELBY R, NISBET-BROWN E, BASRAN RK, CHANG LB, OLIVIERI NF: Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood (1997) 90:891–893.
   PubMed Web of Science ®Google Scholar
• DOVER GJ, BRUSILOW S, SAMID D: Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl. Med. (1992) 327:569–570.
   PubMed Web of Science ®Google Scholar
• LITTLE JA, DEMPSEY NJ, TUCHMAN M, GINDER GD: Metabolic persistence of fetal hemoglobin. Blood (1995) 85:1712–1718.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RK, DOVER G, YOUNG NS et al.: 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J. Clin. Invest. (1985) 75:547–557.
   PubMed Web of Science ®Google Scholar
• KOSHY M, DORN L, BRESSLER L et al.: 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood (2000) 96:2379–2384.
   PubMed Web of Science ®Google Scholar
• •Perhaps these studies will reactivate the field of inducing hypomethylation to permit y-globin gene expression in adults.
   Google Scholar
• STEINBERG MH, LU Z-H, BARTON FB, TERRIN ML, CHARACHE S, DOVER GJ, MULTICENTER STUDY OF HYDROXYUREA: Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood (1997) 89:1078–1088.
   PubMed Web of Science ®Google Scholar
• TAGGER AY, BOUX J, WRIGHT JA: Hydroxy['4C]urea uptake by normal and transformed human cells: evidence for a mechanism of passive diffusion. Biochem. Cell Biol. (1987) 65:925–929.
   PubMed Web of Science ®Google Scholar
• TIMSON J: Hydroxyurea. Mutat Res. (1975) 32:115–132.
   Google Scholar
• STEVENS MR: Hydroxyurea: an overview. Biol. Regal. Homeost. Agents (1999) 13:172–175.
   PubMed Web of Science ®Google Scholar
• GWILT PR, TRACEWELL WG: Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Phannacokinet. (1998) 34:347–358.
   PubMed Web of Science ®Google Scholar
• COLVIN M, BONO VH: The enzymatic reduction of hydroxyurea to urea by mouse liver. Cancer Research (1970) 30:1516–1517.
   PubMed Web of Science ®Google Scholar
• ANDRAE U: Evidence for involvement ofCytochrome P450-dependant monwdgenase in the formation of genotoxic metabolites from N-Hydroxyurea. Biochem. Biophys. Res. Commun. (1984) 118:409–415.
   PubMed Web of Science ®Google Scholar
• FISHBEIN WN, CARBONE PP: Hydroxyurea: mechanisms of action. Science (1963) 142:1069–1070.
   PubMed Web of Science ®Google Scholar
• YARBRO JW: Mechanism of action of hydroxyurea. Semin. Oncol (1992) 19:1–10.
   PubMed Web of Science ®Google Scholar
• LETVIN NL, LINCH DC, BEARDSLEY P, MCINTYRE KW, NATHAN DG: Augmentation of fetal hemoglobin in anemic monkeys by hydroxyurea. N Engl. I Med. (1984) 310:869–874.
   PubMed Web of Science ®Google Scholar
• PLATT OS, ORKIN SH, DOVER G, BEARDSLEY GP, MILLER B, NATHAN DG: Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. j Clin. Invest. (1984) 74:652–656.
   PubMed Web of Science ®Google Scholar
• CHARACHE S, DOVER GJ, MOYER MA, MOORE RV: Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood (1987) 69:109–116.
   PubMed Web of Science ®Google Scholar
• CHARACHE S, DOVER GJ, MOORE RD et al: Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 79:2555–2565.
   PubMed Web of Science ®Google Scholar
• DOVER GJ, HUMPHRIES RK, MOORE JG et al.: Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood (1986) 67:735–738.
   PubMed Web of Science ®Google Scholar
• CHARACHE S, TERRIN ML, MOORE RD et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl. J. Med. (1995) 332:1317–1322.
   PubMed Web of Science ®Google Scholar
• STEINBERG MH, BARTON F, CASTRO 0, RAMIREZ GM, BELLE VUE R, TERRIN M, MULTICENTER STUDY OF HYDROXYUREA IN SICKLE CELL ANEMIA: Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood(2000) 96:485a.
   Web of Science ®Google Scholar
• •Although reported here only in abstract, further studies strongly suggest that hydroxyurea improves lifespan in adult sickle cell anaemia.
   Google Scholar
• WILSON S: Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann. Intern. Med. (2000) 133:925–926.
   PubMed Web of Science ®Google Scholar
• RAUCH A, BORROMEO M, GHAFOOR A: Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood (1999) 94:415a.
   Web of Science ®Google Scholar
• WEINFELD A, SWOLIN B, WESTIN J: Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eat Haematol (1994) 52:134–139.
   PubMed Web of Science ®Google Scholar
• NAND S, STOCK W, GODWIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am. J. Hematol (1996) 52:42–46.
   PubMed Web of Science ®Google Scholar
• NAJEAN Y, RAIN JD: Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood (1997) 90:3370–3377.
   PubMed Web of Science ®Google Scholar
• NAJEAN Y, RAIN J-D: Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood(1997) 89:2319–2327.
   PubMed Web of Science ®Google Scholar
• FENAUX P, PREUDHOMME C, LAY JL, STERKERS Y: Is hydroxyurea leukemogenic in essential thrombocythemia? Response. Blood (1998) 92:1460–1461.
   Web of Science ®Google Scholar
• STERKERS Y, PREUDHOMME C, LAI JL et al.: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood (1998) 91:616–622.
   PubMed Web of Science ®Google Scholar
• LIOZON E, BRIGAUDEAU C, TRIMOREAU F et al.: Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell The]: (1997) 39:11–18.
   PubMedGoogle Scholar
• BARBUL T, FINAZZI G, RUGGERI M, RIDEGHIERO F: Secondary leukemia following hydroxyurea in patients with essential thromocythemia: long-term results of a randomized clinical trial. Blood (1998) 92:489a.
   Web of Science ®Google Scholar
• PLATT OS, BRAMBILLA DJ, ROSSE WF et al.: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl. J. Med. (1994) 330:1639–1644.
   PubMed Web of Science ®Google Scholar
• SCOTT JP, HILLERY CA, BROWN ER, MISIEWICZ V, LABOTKA RJ: Hydroxyurea therapy in children severely affected with sickle cell disease. I Pediatr. (1996) 128:820–828.
   Web of Science ®Google Scholar
• JAYABOSE S, TUGAL 0, SANDOVAL C et al.: Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J. Pediatt (1996) 129:559–565.
   Google Scholar
• FERSTER A, VERMYLEN C, CORNU G et al.: Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood (1996) 88:1960–1964.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NE VICHINKSY EP: Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. .1. Pediatc Hematol Oncol (1998) 20:26–31.
   Google Scholar
• MAIER-REDELSPERGER M, DE MONTALEMBERT M, FLAHAULT A et al.: Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood (1998) 91:4472–4479.
   PubMed Web of Science ®Google Scholar
• DE MONTALEMBERT M, BEGUE P, BERNAUDIN F et al.: Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch. Dis. Child. (1999) 81:437–439.
   PubMed Web of Science ®Google Scholar
• KINNEY TR, HELMS RW, O'BRANSKI EE et al.: Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a Phase I/II trial. Blood (1999) 94:1550–1554.
   Google Scholar
• PARASURAMAN S, RODMAN JH, WARE RE, LIU A, WYNN L, WANG WC: Pharmacokinetics (PK) of hydroxyurea (HU) in children with sickle cell anemia (SCA). Blood (1998) 92:326.
   Web of Science ®Google Scholar
• WARE RE, EGGLESTON B, REDDING-LALLINGER R et al.: Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 99:10–14.
   PubMed Web of Science ®Google Scholar
• HOPPE C, VAN WARMERDAM J, ALLEN K, QUIRLO K, VICHINSKY E: The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program (1999):99.
   Google Scholar
• ROGERS ZR, WARE RE, WYNN LW, SCOTT JP, LANE PA, WANG WC: Extension of the pilot trial of hydroxyurea (HU) in very young children with sickle cell anemia (SCA). 24th Annual Meeting of the National Sickle Cell Disease Program (2000):55a.
   Google Scholar
• STEINBERG MH, NAGEL RL, BRUGNARA C: Cellular effects of hydroxyurea in Hb SC disease. Br. Haematol (1997) 98:838–844.
   PubMed Web of Science ®Google Scholar
• WARE RE, SOMMERICH M, ZIMMERMAN SA, O'BRANSKI EE, SCHULTZ WH: Hydroxyurea therapy for pediatric patients with Hemoglobin SC disease: laboratory and clinical effects. 23rd Annual meeting of the National Sickle Cell Disease Program (1999):170.
   Google Scholar
• IYER R, BALIGA R, NAGEL RL et al.: Maximum urine concentrating ability in children with Hb SC disease: Effects of hydroxyurea. Am. J. Hematol (2000) 64:47–52.
   PubMed Web of Science ®Google Scholar
• HILLIARD L, MADDOX M, HOWARD T: Hydroxyurea in pediatric patients with hemoglobin SC disease. 25th Annual Meeting of the National Sickle Cell Disease Program (2001):98a.
   Google Scholar
• CHARACHE S, BARTON FB, MOORE RD et al.: Hydroxyurea and sickle cell anemia - clinical utility of a myelosuppressive 'switching' agent. Medicine (Baltimore) (1996) 75:300–326.
   PubMed Web of Science ®Google Scholar
• FADLON E, VORDERMEIER S, PEARSON TC et al.: Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood (1998) 91:266–274.
   PubMed Web of Science ®Google Scholar
• HEBBEL RP, BOOGAERTS MA, EATON JW, STEINBERG MH: Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N. Engl. J. Med. (1980) 302:992–995.
   PubMed Web of Science ®Google Scholar
• SUGIHARA K, SUGIHARA T, MOHANDAS N, HEBBEL RP: Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood (1992) 80:2634–2642.
   PubMed Web of Science ®Google Scholar
• WICK TM, MOAKE JL, UDDEN MM, MCINTIRE LV: Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am. .1. Hematol (1993) 42:284–292.
   PubMed Web of Science ®Google Scholar
• SWERLICK RA, ECKMAN JR, KUMAR A, JEITLER M, WICK TM: a4131-Integrin expression on sickle reticulocytes: Vascular cell adhesion molecule- I-dependent binding to endothelium. Blood (1993) 82: 1891-1899.
   Google Scholar
• GEE BE, PLATT OS: Sickle reticulocytes adhere to VCAM-1. Blood(1995) 85:268–274.
   PubMed Web of Science ®Google Scholar
• BRITTAIN HA, ECKMAN JR, SWERLICK RA, HOWARD RJ, WICK TM: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood (1993) 81:2137–2143.
   PubMed Web of Science ®Google Scholar
• JONECKIS CC, ACKLEY RL, ORRINGER EP, WAYNER EA, PARISE LV: Integrin a431 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood (1993) 82:3548–3555.
   PubMed Web of Science ®Google Scholar
• ADRAGNA NC, FONSECA P, LAUF PK: Hydroxyurea affects cell morphology cation transport and red blood cell adhesion in cultured vascular endothelial cells. Blood (1994) 83:553–560.
   PubMed Web of Science ®Google Scholar
• STYLES LA, LUBIN B, VICHINSKY E et al.: Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood (1997) 89:2554–2559.
   PubMed Web of Science ®Google Scholar
• SETTY BN, KULKARNI S, DAMPIER CD, STUART MJ: Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood (2001) 97:2568–2573.
   PubMed Web of Science ®Google Scholar
• SALEH AW, HILLEN HFP, DUITS AJ: Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol (1999) 102:31–37.
   PubMed Web of Science ®Google Scholar
• HILLERY CA, DU MC, WANG WC, SCOTT JP: Hydroxyurea therapy decreases the M vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br. Haematol (2000) 109:322–327.
   PubMed Web of Science ®Google Scholar
• BRIDGES KR, BARABINO GD, BRUGNARA C et al.: A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood (1996) 88:4701–4710.
   PubMed Web of Science ®Google Scholar
• BALLAS SK, DOVER GJ, CHARACHE S: Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am. .1. Hematol (1991) 32:104–111.
   Web of Science ®Google Scholar
• SATO K, AKAIKE T, SAWA T et al.: Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. fpn. I Cancer Res. (1997) 88:1199–1204.
   PubMed Web of Science ®Google Scholar
• JIANG J, JORDAN SJ, BARR DP, GUNTHER MR, MAEDA H, MASON RP: In vivo production of nitric oxide in rats after administration of hydroxyurea. Pharmacol (1997) 52:1081–1086.
   Web of Science ®Google Scholar
• XU YP, MULL CD, BONIFANT CL et at Nitrosylation of sickle cell hemoglobin by hydroxyurea. J. Org. Chem. (1998) 63:6452–6453.
   PubMed Web of Science ®Google Scholar
• GLOVER RE, IVY ED, ORRINGER EP, MAEDA H, MASON RP: Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol. Pharmacol. (1999) 55:1006–1010.
   PubMed Web of Science ®Google Scholar
• PAPASSOTIRIOU I, STAMOULAKATOU A, VOSKARIDOU E, STAMOU E, LOUKOPOULOS D: Hydroxyurea induced erythropoietin secretion in sickle cell syndromes may contribute in their HbF increase. Blood(1998) 92:160a.
   PubMed Web of Science ®Google Scholar
• KIM-SHAPIRO DB, KING SB, BONIFANT CL, BALLAS SK: Hydroxyurea reacts with sickle cell hemoglobin to form methemoglobin and other minor species. Blood(1997) 90:286.
   Web of Science ®Google Scholar
• ADAMS-GRAVES P, KEDAR A, KOSHY M et al: RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study. Blood (1997) 90:2041–2046.
   PubMed Web of Science ®Google Scholar
• ORRINGER EP, CASELLA JF, ATAGA KI et al.: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA (2001) 286:2099–2106.
   PubMed Web of Science ®Google Scholar
• SOLOVEY AA, SOLOVEY AN, HARKNESS J, HEBBEL RP: Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood (2001) 97:1937–1941.
   PubMed Web of Science ®Google Scholar
• MOSSERI M, BARTLETT-PANDITE AN, WENC K, ISNERJM, WEINSTEIN R: Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am. Heart (1993) 126:338–346.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN R, ZHOU M, BARTLETT-PANDITE A, WENC K: Sickle erythrocytes inhibit human endothelial cell DNA synthesis. Blood(1990) 76:2146–2152.
   PubMed Web of Science ®Google Scholar
• KAUL DK, TSAI HM, LIU XD, NAKADA MT, NAGEL RL, COLLER BS: Monoclonal antibodies to aV33 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood (2000) 95:368–374.
   PubMed Web of Science ®Google Scholar
• •These studies point to new ways of interfering with sickle-endothelial cell adhesion.
   Google Scholar
• BARABINO GA, LIU XD, EWENSTEIN BM, KAUL DK: Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood (1999) 93:1422–1429.
   PubMed Web of Science ®Google Scholar
• KAUL DK, LIU X, NAGEL RL: Ameliorating effects of fluorocarbon emulsion on sickle red blood cell- induced obstruction in an ex vivovasculature. Blood (2001) 98:3128–3131.
   PubMed Web of Science ®Google Scholar
• •This is still another means of re-establishing flow in vessels occluded by sickle cells.
   Google Scholar
• EMBURY SH, HEBBEL RP, STEINBERG MH, MOHANDAS N: Pathogenesis of vasoocclusion. In: Sickle Cell Disease: Basic Principles and Clinical Practice (1st edn). Lippincott-Raven, New York, USA (1994):311–326.
   Google Scholar
• HEBBEL RP: Adhesive interactions of sickle erythrocytes with endothelium. J. Clin. Invest. (1997) 99:2561–2564.
   PubMed Web of Science ®Google Scholar
• FABRY ME, NAGEL RL: The effect of deoxygenation on red cell density: significance for the pathophysiology of sickle cell anemia. Blood(1982) 60:1370–1377.
   PubMed Web of Science ®Google Scholar
• FABRY ME, MEARS JG, PATEL P et al.: Dense cells in sickle cell anemia: the effects of gene interaction. Blood (1984) 64:1042–1046.
   PubMed Web of Science ®Google Scholar
• MOHANDAS N, KIM YR, TYCKO DH, ORLIK J, WYATT J, GRONER W: Accurate and independent measurement of volume and hemoglobin concentration of individual cells by laser light scattering. Blood (1986) 68:506–513.
   PubMed Web of Science ®Google Scholar
• MOHANDAS N, JOHNSON H, WYATT J et al.: Automated quantitation of cell density distribution and hyperdense cell fraction in RBC disorders. Blood (1989) 74:442–447.
   PubMed Web of Science ®Google Scholar
• MOHANDAS N, BALLAS SK: Erythrocyte density and heterogeneity. In: Sickle Cell Disease: Basic Principles and Clinical Practice. 1st edn. Raven Press, New York, USA (1994):195–204.
   Google Scholar
• EATON WA, HOFRICHTER J: Hemoglobin S gelation and sickle cell disease. Blood (1987) 70:1245–1266.
   PubMed Web of Science ®Google Scholar
• EMBURY SH, CLARK MR, MONROY GM, MOHANDAS N: Concurrent sickle cell anemia and a thalassemia. Clin. Invest. (1984) 73:116–123.
   Google Scholar
• SUNSHINE HR, HOFRICHTER J, EATON WA: Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature (1978) 275:238–240.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, BUNN HF, TOSTESON DC: Regulation of erythrocyte cation and water content in sickle cell anemia. Science (1986) 232:388–390.
   PubMed Web of Science ®Google Scholar
• CANESSA M, SPLAVINS A, NAGEL RL: Volume-dependent and NEM-stimulated K+Cl- transport is elevated in oxygenated SS SC and CC human cells. FEBS Lett. (1986) 200:197–202.
   PubMed Web of Science ®Google Scholar
• JOINER CH: Cation transport and volume regulation in sickle red blood cells. Am. Physiol Cell Physiol (1993) 264:C251–C270.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, VAN HA T, TOSTESON DC: Acid pH induces formation of dense cells in sickle erythrocytes. Blood (1989) 74:487–495.
   PubMed Web of Science ®Google Scholar
• CANESSA M, FABRY ME, BLUMENFELD N, NAGEL R: A volume- stimulateddependent K+ efflux is highlyexpressed in young human red cells containing normal hemoglobin or Hb S. Membr. Biol. (1987) 97:97–105.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, KOPIN AS, BUNN HF, TOSTESON DC: Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease. J. Clin. Invest. (1985) 75:1608–1617.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C: Characteristics of the volume- and chloride-dependent K transport in human erythrocytes homozygous for hemoglobin C. Mem& Biol. (1989) 111:69–81.
   PubMed Web of Science ®Google Scholar
• OLIVIERI 0, VITOUX D, GALACTEROS F et al: Hemoglobin variants and activity of the (K+C1-) cotransport system in human erythrocytes. Blood (1992) 79:793–797.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, DE FRANCESCHI L, ALPER SL: Inhibition of Ca2+-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J. Clin. Invest. (1993) 92:520–526.
   PubMed Web of Science ®Google Scholar
• GARDOS G: The function of calcium in the potassium permeability of human erythrocytes. Biochim. Biophys. Acta (1958) 30:653–654.
   PubMed Web of Science ®Google Scholar
• OHNISHI ST, HORIUCHI KY, HORIUCHI K: The mechanism of M vitro formation of irreversibly sickled cells and modes of action of its inhibitors. Biochim. Biophys. Acta (1986) 886:119–129.
   PubMed Web of Science ®Google Scholar
• HORIUCHI K, ASAKURA T: Formation of light irreversibly sickled cells during deoxygenation- oxygenation cycles. Lab. Clin. Med. (1987) 110:653–660.
   PubMed Web of Science ®Google Scholar
• HORIUCHI K, BALLAS SK, ASAKURA T: The effect of deoxygenation rate on the formation of irreversibly sickled cells. Blood (1988) 71:46–51.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, DE FRANCES CHI L, ALPER SL: Ca(2+)-activated K+ transport in erythrocytes. Comparison of binding and transport inhibition by scorpion toxins. J. Biol. Chem. (1993) 268:8760–8768.
   Google Scholar
• RHODA MD, APOVO M, BEUZARD Y, GIRAUD F: Ca2+ permeability in deoxygenated sickle cells. Blood (1990) 75:2453–2458.
   PubMed Web of Science ®Google Scholar
• BOOKCHIN PM, ORTIZ OE, LEW VL: Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J. Clin. Invest. (1991) 87:113–124.
   PubMed Web of Science ®Google Scholar
• ETZION Z, TIFFERT T, BOOKCHIN RM, LEW VL: Effects of deoxygenation on active and passive Ca2+ transport and on the cytoplasmic Ca2+ levels of sickle cell anemia red cells. J. Clin. Invest. (1993) 92:2489–2498.
   PubMed Web of Science ®Google Scholar
• TIFFERT T, SPIVAK JL, LEW VL: Magnitude of calcium influx required to induce dehydration of normal human red cells. Biochim. Biophys. Acta (1988) 943:157–165.
   PubMed Web of Science ®Google Scholar
• LI Q, JUNGMANN V, KIYATKIN A, LOW PS: Prostaglandin E2 stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability. J. Biol. Chem. (1996) 271:18651–18656.
   PubMed Web of Science ®Google Scholar
• RIVERA A, ROTTER MA, BRUGNARA C: Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes. Am. J. Physic] (1999) 277:C746–C754.
   Web of Science ®Google Scholar
• RIVERA A, JAROLIMP, BRUGNARA C: Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood (2002) 99:357–363.
   PubMed Web of Science ®Google Scholar
• RYBICKI AC, BENJAMIN LJ: Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood (1998) 92:2594–2596.
   PubMed Web of Science ®Google Scholar
• WERDEHOFF SG, MOORE RB, HOFF CJ, FILLINGIM E, HACKMAN AM: Elevated plasma endothelin-1 levels in sickle cell anemia: Relationships to oxygen saturation and left ventricular hypertrophy. Am. J. Hematol (1998) 58:195–199.
   PubMed Web of Science ®Google Scholar
• HAMMERMAN SI, KOUREMBANAS S, CONCA TJ, TUCCI M, BRAUER M, FARBER HW: Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am. J. Respic Grit. Care Med. (1997) 156:280–285.
   PubMed Web of Science ®Google Scholar
• PHELAN M, PERRINE SP, BRAUER M, FALLER DV: Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J. Gin. Invest. (1995) 96:1145–1151.
   PubMed Web of Science ®Google Scholar
• TOSTESON DC: The effects of sickling on ion transport. II The effect of sickling on sodium and cesium transport." Gen. Physiol (1955) 39:55–67.
   Google Scholar
• TOSTESON DC, CARLSEN E: The effects of sickling on ion transport. I Effect of sickling on potassium transport. " Gen. Physiol (1955) 39:31–53.
   PubMed Web of Science ®Google Scholar
• TOSTESON DC, SHEA E: Potassium and sodium of red blood cells in sickle cell anemia.j Clin. Invest. (1952) 31:406–411.
   PubMed Web of Science ®Google Scholar
• JOINER CH, DEW A, GE DL: Deoxygenation-induced cation fluxes in sickle cells: relationship between net potassium efflux and net sodium influx. Blood Cells (1988) 13:339–358.
   PubMedGoogle Scholar
• JOINER CH: Deoxygenation-induced cation fluxes in sickle cells: II. Inhibition by stilbene disulfonates. Blood (1990) 76:212–220.
   PubMed Web of Science ®Google Scholar
• JOINER CH, MORRIS CL, COOPER ES: Deoxygenation-induced cation fluxes in sickle cells. III. Cation selectivity and response to pH and membrane potential. Am. I Physiol Cell Physiol (1993) 264:C734–C744.
   PubMed Web of Science ®Google Scholar
• JOINER CH, JIANG M, FRANCO RS: Deoxygenation-induced cation fluxes in sickle cells. IV. Modulation by external calcium. Am. Physiol Cell Physiol (1995) 269:C403–C409.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ LR, ORRINGER EP: Passive sodium and potassium movements in sickle erythrocytes. Am. Physic] (1985) 249:C208–C214.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, TOSTESON DC: Inhibition of K transport by divalent cations in sickle erythrocytes. Blood (1987) 70:1810–1815.
   PubMed Web of Science ®Google Scholar
• OLUKOGA AO, ADEWOYE HO, ERASMUS RT, ADEDOYIN MA: Erythrocyte and plasma magnesium in sickle-cell anaemia. East Afr. Med. J. (1990) 67:348–354.
   PubMed Web of Science ®Google Scholar
• ORTIZ OE, LEW VL, BOOKCHIN PM: Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells. J. Physic] (1990) 427:211–226.
   Google Scholar
• DE FRANCESCHI L, BACHIR D, GALACTEROS F et al.: Oral magnesium Supplements reduce erythrocyte dehydration in patients with sickle cell disease." Clin. Invest. (1997) 100:1847–1852.
   Google Scholar
• RIVERA A, FERREIRA AM, ROMERO J, BRUGNARA C: Characterization of Na+/ Mg+ exchange in sickle erythrocytes. Blood (2001) 98:485a.
   Web of Science ®Google Scholar
• BORELLA P, AMBROSINI G, CONCARI M, BARGELLINI A: Is magnesium content in erythrocytes suitable for evaluating cation retention after oral physiological Supplementation in marginally magnesium-deficient subjects? Magnes. Res. (1993) 6:149–153.
   Google Scholar
• PAOLISSO G, SCHEEN A, COZZOLINO D et al.: Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (Type II) diabetic patients." Clin. Endocrinol Metab. (1994) 78:1510–1514.
   Google Scholar
• DE FRANCESCHI L, BEUZARD Y, JOUAULT H, BRUGNARA C: Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood (1996) 88:2738–2744.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCHI L, BACHIR D, GALACTEROS F et al.: Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br. Haematol (2000) 108:284–289.
   PubMed Web of Science ®Google Scholar
• •Altering cell dehydration is a promising approach to treating sickle cell disease.
   Google Scholar
• ALVAREZ J, MONTERO M, GARCIA-SANCHO J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P450 inhibitors." Biol. Chem. (1992) 267:11789–11793.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, ARMSBY CC, SAKAMOTO M, RIFAI N, ALPER SL, PLATT 0: Oral administration of clotrimazole and blockade of human erythrocyte Ca-activated K+ channel: The imidazole ring is not required for inhibitory activity." Pharmacol Exp. The]: (1995) 273:266–272.
   Google Scholar
• RIFAI N, SAKAMOTO M, LAW T et al: HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. Gin. Chem. (1995) 41:387–391.
   Web of Science ®Google Scholar
• DE FRANCESCHI L, SAADANE N, TRUDEL M, ALPER SL, BRUGNARA C, BEUZARD Y: Treatment with oral clotrimazole blocks Ca2+-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J. Clin. Invest. (1994) 93:1670–1676.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C, GEE B, ARMSBY CC et al.: Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease." Clin. Invest. (1996) 97:1227–1234.
   Google Scholar
• RIGDON G, STOCKER JVV, MCNAUGHTON-SMITH G, HULL H,LESSE P: A Phase I safety pharmacokinetic and pharmacodynamic study of ascending single oral doses of ICA-17043 a novel Gardos channel inhibitor fore the treatment of sickle cell disease. Blood (2000) 96:206.
   Web of Science ®Google Scholar
• STOCKER J, DE FRANCESCHI L, MCNAUGHTON-SMITH G, BRUGNARA C: A novel Gardos channel inhibitor, ICA-17043 prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease. Blood (2000) 96:486a.
   Google Scholar
• BENNEKOU P: The feasibility of pharmacological volume control of sickle cells is dependent on the quantization of the transport pathways. A model study. I Theo]: Biol. (1998) 196:129–137.
   Google Scholar
• BENNEKOU P, STAMPE P: The effect of ATP, intracellular calcium and the anion exchange inhibitor DIDS on conductive anion fluxes across the human red cell membrane. Biochim. Biophys. Acta (1988) 942:179–185.
   PubMed Web of Science ®Google Scholar
• BENNEKOU P, PEDERSEN 0, MOLLER A, CHRISTOPHERSEN P: Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652. Blood (2000) 95: 1842-1848.
   Google Scholar
• BENNEKOU P, DE FRANCESCHI L, PEDERSEN 0 et al.: Treatment with N53623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood(2001) 97:1451–1457.
   Google Scholar
• •This work presents still another means of altering sickle cell dehydation.
   Google Scholar
• JOINER CH, CLAUSSEN W, YASIN Z, FRANCO RS: Dipyridamole inhibits IP vitro deoxygenation-induced cation fluxes in sickle red blood cells at the membrane concentration achievable in blood. Blood (1997) 90:125a.
   Web of Science ®Google Scholar
• GLADWIN MT, SCHECHTER AN, SHELHAMER JH et al: Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. Clin. Invest. (1999) 104:937–945.
   Google Scholar
• GLADWIN MT, OGNIBENE FP, SHELHAMER JH et al.: Nitric oxide transport on sickle cell hemoglobin: where does it bind? Free Radic. Res. (2001) 35:175–180.
   Google Scholar
• STAMLER JS, JIA L, EU JP et al.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science (1997) 276:2034–2037.
   PubMed Web of Science ®Google Scholar
• GOW AJ, STAMLERJS: Reactions between nitric oxide and haemoglobin under physiological conditions. Nature (1998) 391:169–173.
   PubMed Web of Science ®Google Scholar
• JIA L, BONAVENTURA C, BONAVENTURA J, STAMLERJS: nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature194.(1996) 380:221–226.
   Google Scholar
• HEAD CA, BRUGNARA C, MARTINEZ- RUIZ R et al.: Low concentrations of nitric195.oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. Clin. Invest. (1997) 100:1193-1198.1CIR
   Google Scholar
• MONDORO TH, RYAN BB, HRINCZENKO BW, SCHECHTER AN, VOSTAL JG, ALAYASH Al: Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br: J. Haematol (2001) 112:1048–1054.
   PubMed Web of Science ®Google Scholar
• KHAN BV, HARRISON DG, OLBRYCH MT, ALEXANDER RW, MEDFORD PM: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Nati Acad. Sci. USA (1996) 93:9114–9119.
   PubMed Web of Science ®Google Scholar
• SPACE SL, LANE PA, PICKETT CK, WEIL JV: Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am. I Hematol (2000) 63:200–204.
   PubMed Web of Science ®Google Scholar
• PALMER RM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• BELHASSEN L, PELLE G, SEDIAME S et al.: Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood (2001) 97:1584–1589.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, II, KENNY D, SCOTT JP et al: Mechanisms of stroke in sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood(1997) 89:4591–4599.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-RUIZ R, MONTERO-HUERTA P, HROMI J, HEAD CA: Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology (2001) 94:1113–1118.
   PubMed Web of Science ®Google Scholar
• LOPEZ BL, DAVIS-MOON L, BALLAS SK, MA XL: Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. Am. Hematol (2000) 64:15–19.
   PubMed Web of Science ®Google Scholar
• MORRIS CR, KUYPERS FA, LARKIN S, VICHINSKY EP, STYLES LA: Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. Pediatr. Hematol Oncol. (2000) 22:515–520.
   Web of Science ®Google Scholar
• REES DC, CERVI P, GRIMWADE D et al: The metabolites of nitric oxide in sickle-cell disease. Br. Haematol (1995) 91:834–837.
   PubMed Web of Science ®Google Scholar
• ATZ AM, WESSEL DL: Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology (1997) 87:988–990.
   PubMed Web of Science ®Google Scholar
• SULLIVAN KJ, GOODWIN SR, EVANGELIST J, MOORE RD, MEHTA P: Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit. Care Med. (1999) 27:2563–2568.
   PubMed Web of Science ®Google Scholar
• LEWIS RS, TAMIR S, TANNENBAUM SR, DEEN WM: Kinetic analysis of the fate of nitric oxide synthesized by macrophages M vitro.j Biol. Chem. (1995) 270:29350–29355.
   PubMed Web of Science ®Google Scholar
• SCHACTER L, WARTH JA, GORDON EM, PRASAD A, KLEIN BL: Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB (1988) 2:237–243.
   PubMed Web of Science ®Google Scholar
• OSAROGIAGBON UR, CHOONG S, BELCHER JD, VERCELLOTTI GM, PALLER MS, HEBBEL RP: Reperfusion injury pathophysiology in sickle transgenic mice. Blood (2000) 96:314–320.
   PubMed Web of Science ®Google Scholar
• HAMMERMAN SI, KLINGS ES, HENDRA KP et al.: Endothelial cell nitric oxide production in acute chest syndrome. Am.Physiol Heart Circ. Physiol (1999)277:H1579–H1592.
   PubMed Web of Science ®Google Scholar
• NATH KA, SHAH V, HAGGARD JJ et al: Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am. I Physiol Regal Integr. Comp. Physiol (2000) 279:R1949–R1955.
   PubMed Web of Science ®Google Scholar
• KLINGS ES, CHRISTMAN BW, MCCLUNG J et al.: Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am. Respir: Crit. Care Med. (2001) 164:1248–1252.
   Google Scholar
• GLADWIN MT, SCHECHTER AN, SHELHAMER JH, OGNIBENE FP: The acute chest syndrome in sickle cell disease - Possible role of nitric oxide in its pathophysiology and treatment. Am. Respir. Crit. Care Med. (1999) 159:1368–1376.
   PubMed Web of Science ®Google Scholar